Scientific article| Volume 34, ISSUE 3, P446-452, March 2009

Download started.


Botulinum Toxin Type A: A Treatment Option for Digital Ischemia in Patients With Raynaud's Phenomenon


      Raynaud's phenomenon is an exaggerated vasospastic response that causes pallor and cyanosis. In the hand, it results in pain, disability, and the need for amputation. Current accepted medical and surgical treatments are not uniformly successful and have their inherent morbidities. Reports in the literature describe the use of botulinum toxin type A (BTX-A) for the treatment of vasospastic ischemia of the digits. We report the results of the treatment of recalcitrant digital ischemia with BTX-A in our institution.


      We performed a retrospective chart review between January 2003 and February 2007. All patients presented with a diagnosis of Raynaud's phenomenon with worsening pain, discoloration, or nonhealing wound of the hand. Patients received BTX-A injections into the perineurovascular tissue of the wrist or the distal palm, or along the digit. Outcomes measured included pain rating, digit color and appearance, transcutaneous oxygen saturation, and healing of chronic ulcers.


      Twenty-six patients were treated, with a total of 55 treatment encounters. Patients were observed for an average of 18 months. Statistically significant improvements were noted for pain score and digit transcutaneous oxygen saturation measurements after treatment (p < .05). We found smokers and women were more likely to have improved coloration and appearance after injections. Complications included localized injection-related pain and transient intrinsic muscle weakness.


      Botulinum toxin type A significantly improves pain and improves healing in Raynaud's patients with few complications. BTX-A was found to be a safe and useful treatment option for vasospastic digital ischemia.

      Type of study/level of evidence

      Therapeutic IV.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hand Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • LeRoy E.C.
        • Medsger Jr, T.A.
        Raynaud's phenomenon: a proposal for classification.
        Clin Exp Rheumatol. 1992; 10 (485–458.)
        • Hummers L.K.
        • Wigley F.M.
        Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.
        Rheum Dis Clin North Am. 2003; 29: 293-313
        • Grader-Beck T.
        • Wigley F.M.
        Raynaud's phenomenon in mixed connective tissue disease.
        Rheum Dis Clin North Am. 2005; 31 (, vi.): 465-481
        • Thompson A.E.
        • Shea B.
        • Welch V.
        • Fenlon D.
        • Pope J.E.
        Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
        Arthritis Rheum. 2001; 44: 1841-1847
        • Pope J.
        • Fenlon D.
        • Thompson A.
        • Shea B.
        • Furst D.
        • Wells G.
        • et al.
        Prazosin for Raynaud's phenomenon in progressive systemic sclerosis.
        Cochrane Database Syst Rev. 1998; (Issue 2. Art. No. CD000956.)
        • Flatt A.E.
        Digital artery sympathectomy.
        J Hand Surg. 1980; 5: 550-556
        • Wilgis E.F.
        Digital sympathectomy for vascular insufficiency.
        Hand Clin. 1985; 1: 361-367
        • Tomaino M.M.
        • Goitz R.J.
        • Medsger T.A.
        Surgery for ischemic pain and Raynaud's phenomenon in scleroderma: a description of treatment protocol and evaluation of results.
        Microsurgery. 2001; 21: 75-79
        • Thompson A.E.
        • Pope J.E.
        Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.
        Rheumatology (Oxford). 2005; 44: 145-150
        • Sycha T.
        • Graninger M.
        • Auff E.
        • Schnider P.
        Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study.
        Eur J Clin Invest. 2004; 34: 312-313
        • Van Beek A.L.
        • Lim P.K.
        • Gear A.J.
        • Pritzker M.R.
        Management of vasospastic disorders with botulinum toxin A.
        Plast Reconstr Surg. 2007; 119: 217-226
        • Williamson A.
        • Hoggart B.T.
        Pain: a review of three commonly used pain rating scales.
        J Clin Nurs. 2005; 14: 798-804
      1. Primer of Biostatistics. Glantz, McGraw-Hill, New York1996: 85-102 (version 4.02.)
        • Morris J.L.
        • Jobling P.
        • Gibbins I.L.
        Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons.
        Am J Physiol Heart Circ Physiol. 2001; 281: H2124-H2132
        • Matic D.B.
        • Lee T.Y.
        • Wells R.G.
        • Gan B.S.
        The effects of botulinum toxin type A on muscle blood perfusion and metabolism.
        Plast Reconstr Surg. 2007; 120: 1823-1833
        • Freitag F.G.
        Botulinum toxin type A in chronic migraine.
        Expert Rev Neurother. 2007; 7: 463-470
        • Costa J.
        • Espírito-Santo C.
        • Borges A.
        • Ferreira J.J.
        • Coelho M.
        • Moore P.
        • et al.
        Botulinum toxin type A therapy for cervical dystonia.
        Cochrane Database Syst Rev. 2005; (Issue 1. Art. No. CD003633.)
        • Brin M.F.
        • Lyons K.E.
        • Doucette J.
        • Adler C.H.
        • Caviness J.N.
        • Comella C.L.
        • et al.
        A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.
        Neurology. 2001; 56: 1523-1528
        • Picart C.
        • Carpentier P.H.
        • Brasseur S.
        • Galliard H.
        • Piau J.M.
        Systemic sclerosis: blood rheometry and laser Doppler imaging of digital cutaneous microcirculation during local cold exposure.
        Clin Hemorheol Microcirc. 1998; 18: 47-58